Mavacamten
Active Pharmaceutical Ingredients 2025-03-03
MYK-461 (SAR-439152) 6-([(1S)-1-Phenylethyl]amino)-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione 6-[[(1S)-1-Phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
Catalog ID101886
CAS NO.1642288-47-8
MDL NumberMFCD31746877
EINEC Molecular Formula C15H19N3O2
Molecular weight 273.33
| Category | Content |
|---|---|
| Drug Name | Mavacamten (Brand Name: Camzyos) |
| Drug Class | Miscellaneous cardiovascular agents |
| Mechanism of Action | Selective allosteric and reversible cardiac myosin inhibitor. It binds to myosin in the heart muscle, reducing left ventricular outflow tract obstruction and improving cardiac filling pressures. |
| Indications | Symptomatic obstructive hypertrophic cardiomyopathy (HCM) in adults, classified as New York Heart Association (NYHA) class II-III, to improve functional capacity and symptoms. |
| Dosage Forms | Capsules (2.5mg, 5mg, 10mg, 15mg) |
| Side Effects | Common: Dizziness (27%) or fainting (6%). Serious: Heart failure symptoms (e.g., shortness of breath, chest pain, swelling in legs), allergic reactions. |
| Approval Date | FDA approval on April 28, 2022 |
| Clinical Trials | EXPLORER-HCM trial: Showed significant improvements in LVOT gradient, NYHA classification, and exercise performance. VALOR-HCM trial: Demonstrated reduced need for septal reduction therapies. |
| Developer | MyoKardia (subsidiary of Bristol Myers Squibb) |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
